DBV Technologies S.A.
DBVT
NASDAQ·Healthcare·Biotechnology·Mkt cap $322.2M
$13.47
▼ -1.68%
P/E
-6.41
Mkt Cap
$322.2M
52-Wk Range
$8.70–$26.19
52-Week Range
$8.70 - $26.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 54.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -0.2).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-15.8% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying DBVT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 16, 2026
Reported EPS of -$0.14 vs -$0.12 consensus (-14.3% surprise). Revenue of $800.2K vs $778.2K expected (+2.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-14.3%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jun 30, 2026
vs Industry
How DBVT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.